BRPI0411103B1 - método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo - Google Patents
método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo Download PDFInfo
- Publication number
- BRPI0411103B1 BRPI0411103B1 BRPI0411103A BRPI0411103A BRPI0411103B1 BR PI0411103 B1 BRPI0411103 B1 BR PI0411103B1 BR PI0411103 A BRPI0411103 A BR PI0411103A BR PI0411103 A BRPI0411103 A BR PI0411103A BR PI0411103 B1 BRPI0411103 B1 BR PI0411103B1
- Authority
- BR
- Brazil
- Prior art keywords
- plasma
- autoantibody
- blood
- autoantibodies
- biological fluid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 97
- 239000013060 biological fluid Substances 0.000 title claims description 36
- 239000000284 extract Substances 0.000 title claims description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 111
- 239000008280 blood Substances 0.000 claims abstract description 109
- 230000027455 binding Effects 0.000 claims abstract description 64
- 239000007800 oxidant agent Substances 0.000 claims abstract description 36
- 230000008859 change Effects 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims description 83
- 210000002381 plasma Anatomy 0.000 claims description 66
- 229940025294 hemin Drugs 0.000 claims description 51
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical group CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 31
- 238000003556 assay Methods 0.000 claims description 22
- 210000004700 fetal blood Anatomy 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229930002875 chlorophyll Natural products 0.000 claims description 3
- 235000019804 chlorophyll Nutrition 0.000 claims description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical group C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 2
- 239000012286 potassium permanganate Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 60
- 102000004169 proteins and genes Human genes 0.000 abstract description 59
- 102000004506 Blood Proteins Human genes 0.000 abstract description 29
- 108010017384 Blood Proteins Proteins 0.000 abstract description 28
- 239000010836 blood and blood product Substances 0.000 abstract description 6
- 229940125691 blood product Drugs 0.000 abstract description 6
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 239000003918 blood extract Substances 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 66
- 235000018102 proteins Nutrition 0.000 description 56
- 238000002474 experimental method Methods 0.000 description 44
- 210000003743 erythrocyte Anatomy 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000011534 incubation Methods 0.000 description 25
- 208000023275 Autoimmune disease Diseases 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 238000007630 basic procedure Methods 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 210000001616 monocyte Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000010439 graphite Substances 0.000 description 10
- 229910002804 graphite Inorganic materials 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 10
- 150000003904 phospholipids Chemical class 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 7
- 101710148556 Methylcarbamoylase mom Proteins 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 239000003610 charcoal Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 108010077861 Kininogens Proteins 0.000 description 5
- 102000010631 Kininogens Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000006479 redox reaction Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000003245 coal Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 235000012711 vitamin K3 Nutrition 0.000 description 3
- 239000011652 vitamin K3 Substances 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000013271 Hemopexin Human genes 0.000 description 2
- 108010026027 Hemopexin Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002529 anti-mitochondrial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 210000004492 nuclear pore Anatomy 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 102000036213 phospholipid binding proteins Human genes 0.000 description 2
- 108091011000 phospholipid binding proteins Proteins 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- -1 plasma or serum Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000016955 Erythrocyte Anion Exchange Protein 1 Human genes 0.000 description 1
- 108010014384 Erythrocyte Anion Exchange Protein 1 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 229910015400 FeC13 Inorganic materials 0.000 description 1
- 229910001335 Galvanized steel Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000229537 Moxostoma Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- JQRLYSGCPHSLJI-UHFFFAOYSA-N [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JQRLYSGCPHSLJI-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000008397 galvanized steel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rehabilitation Therapy (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47660703P | 2003-06-09 | 2003-06-09 | |
| PCT/US2004/017889 WO2004111608A2 (en) | 2003-06-09 | 2004-06-09 | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0411103A BRPI0411103A (pt) | 2006-07-18 |
| BRPI0411103B1 true BRPI0411103B1 (pt) | 2019-01-15 |
Family
ID=33551622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411103A BRPI0411103B1 (pt) | 2003-06-09 | 2004-06-09 | método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7368542B2 (enExample) |
| EP (1) | EP1631314B1 (enExample) |
| JP (1) | JP4662557B2 (enExample) |
| CN (1) | CN1832756A (enExample) |
| AT (1) | ATE518886T1 (enExample) |
| AU (1) | AU2004248155B2 (enExample) |
| BR (1) | BRPI0411103B1 (enExample) |
| CA (1) | CA2524325C (enExample) |
| WO (1) | WO2004111608A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368542B2 (en) | 2003-06-09 | 2008-05-06 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| US9557325B2 (en) * | 2003-06-09 | 2017-01-31 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of proteins by oxidation-reduction reactions |
| US7892751B2 (en) | 2003-06-09 | 2011-02-22 | Redox-Reactive Reagents Llc | Method of detecting or diagnosing of a neurodegenerative disease or condition |
| CA2584211C (en) * | 2004-10-22 | 2014-07-08 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| KR101322247B1 (ko) * | 2007-09-06 | 2013-10-25 | 삼성전자주식회사 | 진공청소기용 흡입브러시 및 그 높이조절방법 |
| JP5963341B2 (ja) * | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
| US7989596B2 (en) * | 2007-09-19 | 2011-08-02 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions |
| JP5565607B2 (ja) | 2009-07-15 | 2014-08-06 | 国立大学法人 東京大学 | 敗血症又は多臓器不全の予後診断方法及び予後診断用キット |
| WO2011094535A2 (en) * | 2010-01-28 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| ES2684976T3 (es) | 2012-04-13 | 2018-10-05 | Diabetomics, Inc. | Biomarcadores maternos para diabetes gestacional |
| EP2996772B1 (en) | 2013-05-13 | 2018-12-19 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| US10633453B2 (en) | 2013-05-28 | 2020-04-28 | Kaohsiung Medical University | Antibody locker for the inactivation of protein drug |
| NZ720949A (en) | 2013-12-09 | 2019-03-29 | Univ Leland Stanford Junior | Methods and compositions for treating aging-associated conditions |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| SI3307296T1 (sl) | 2015-06-15 | 2022-04-29 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj |
| KR20180032489A (ko) * | 2016-09-22 | 2018-03-30 | 아주대학교산학협력단 | 액상 플라즈마를 이용한 건선의 예방 또는 치료 방법 |
| KR20180032490A (ko) * | 2016-09-22 | 2018-03-30 | 아주대학교산학협력단 | 액상 플라즈마를 이용한 아토피성 피부염의 예방 또는 치료 방법 |
| US11583689B2 (en) * | 2016-09-22 | 2023-02-21 | Ajou University Industry-Academic Cooperation Foundation | Composition for atopy or psoriasis treatment comprising liquid type plasma |
| KR101933920B1 (ko) | 2016-09-22 | 2018-12-31 | 아주대학교 산학협력단 | 액상 플라즈마를 이용한 비만의 예방 또는 치료 방법 |
| EA201991353A1 (ru) | 2016-12-09 | 2019-11-29 | Двухвалентные антитела, маскированные спирализованными спиралями | |
| US11510853B2 (en) | 2017-09-18 | 2022-11-29 | Ajou University Industry-Academic Cooperation Foundation | Composition for skin soothing containing liquid-phase plasma |
| PE20220383A1 (es) * | 2019-04-18 | 2022-03-18 | Janssen Biotech Inc | Glicoproteinas sialiladas |
| EP3756648A1 (en) * | 2019-06-27 | 2020-12-30 | Imnate Sarl | Improved vaccine formulations |
| TR202016418A2 (tr) * | 2020-10-14 | 2022-04-21 | Serkan Tunc | Kan plazmasinin üzeri̇nden elektri̇k akiminin geçi̇ri̇lmesi̇yle i̇çeri̇si̇nde ölü bakteri̇, parazi̇t vi̇rüs vb. kalintilarin oluştuğu yeni̇ plazmanin canli vücuduna serum olarak veri̇lmesi̇yle bağişiklik geli̇şti̇rme yöntemi̇ |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632980A (en) * | 1985-04-03 | 1986-12-30 | Immunologics | Ozone decontamination of blood and blood products |
| US4703001A (en) | 1985-10-23 | 1987-10-27 | Synbiotics, Corporation | Immunoassay for the detection of serum analytes using pH dependent chastropic acids |
| US4950612A (en) * | 1987-12-16 | 1990-08-21 | Microgenics Corporation | Peroxy acid pretreatment in vitamin B12 assay |
| ATE88453T1 (de) * | 1988-02-22 | 1993-05-15 | Fina Research | Katalytisches einstufenverfahren zur direkten umwandlung von polysacchariden in mehrwertige alkohole. |
| US5061790A (en) * | 1989-07-10 | 1991-10-29 | Molecular Diagnostics, Inc. | Oxidative denaturation of protein analytes |
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| US6660267B1 (en) * | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| US5880954A (en) * | 1995-12-04 | 1999-03-09 | Thomson; Robert | Continous real time safety-related control system |
| AU703814B2 (en) * | 1995-12-04 | 1999-04-01 | Wyeth | Antioxidant |
| US5939394A (en) * | 1996-01-18 | 1999-08-17 | Fleming & Company | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| FR2794461B1 (fr) * | 1999-06-07 | 2004-01-23 | Lab Francais Du Fractionnement | Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice |
| FR2822238B1 (fr) * | 2001-03-16 | 2003-08-29 | Gemac | Methode et trousse pour le suivi des maladies neurodegeneratives |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| US9557325B2 (en) * | 2003-06-09 | 2017-01-31 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of proteins by oxidation-reduction reactions |
| US7368542B2 (en) | 2003-06-09 | 2008-05-06 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
-
2004
- 2004-06-09 US US10/863,365 patent/US7368542B2/en not_active Expired - Lifetime
- 2004-06-09 AT AT04754487T patent/ATE518886T1/de not_active IP Right Cessation
- 2004-06-09 WO PCT/US2004/017889 patent/WO2004111608A2/en not_active Ceased
- 2004-06-09 AU AU2004248155A patent/AU2004248155B2/en not_active Ceased
- 2004-06-09 CA CA2524325A patent/CA2524325C/en not_active Expired - Fee Related
- 2004-06-09 CN CNA2004800159879A patent/CN1832756A/zh active Pending
- 2004-06-09 EP EP20040754487 patent/EP1631314B1/en not_active Expired - Lifetime
- 2004-06-09 BR BRPI0411103A patent/BRPI0411103B1/pt not_active IP Right Cessation
- 2004-06-09 JP JP2006515229A patent/JP4662557B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-23 US US12/107,819 patent/US8334146B2/en not_active Expired - Fee Related
-
2012
- 2012-12-12 US US13/712,151 patent/US9169317B2/en not_active Expired - Fee Related
-
2015
- 2015-10-27 US US14/923,945 patent/US10072068B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050101016A1 (en) | 2005-05-12 |
| US20080280281A1 (en) | 2008-11-13 |
| EP1631314A4 (en) | 2006-08-16 |
| AU2004248155A1 (en) | 2004-12-23 |
| WO2004111608A2 (en) | 2004-12-23 |
| EP1631314B1 (en) | 2011-08-03 |
| EP1631314A2 (en) | 2006-03-08 |
| US9169317B2 (en) | 2015-10-27 |
| AU2004248155B2 (en) | 2008-10-23 |
| ATE518886T1 (de) | 2011-08-15 |
| JP4662557B2 (ja) | 2011-03-30 |
| BRPI0411103A (pt) | 2006-07-18 |
| CN1832756A (zh) | 2006-09-13 |
| US20130109838A1 (en) | 2013-05-02 |
| US20160046695A1 (en) | 2016-02-18 |
| CA2524325C (en) | 2017-08-01 |
| WO2004111608A3 (en) | 2005-04-07 |
| US10072068B2 (en) | 2018-09-11 |
| US8334146B2 (en) | 2012-12-18 |
| US7368542B2 (en) | 2008-05-06 |
| WO2004111608A8 (en) | 2005-12-29 |
| JP2006526027A (ja) | 2006-11-16 |
| CA2524325A1 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0411103B1 (pt) | método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo | |
| Bresnihan et al. | Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. | |
| Denman et al. | Adoptive transfer of the diseases of New Zealand black mice to normal mouse strains | |
| McIntyre | The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions | |
| US9557325B2 (en) | Method of altering the binding specificity of proteins by oxidation-reduction reactions | |
| Malheiro et al. | Impact of de novo donor‐specific anti‐HLA antibodies on grafts outcomes in simultaneous pancreas–kidney transplantation | |
| Harboe et al. | Synthesis of donor type γG‐globulin following thymus transplantation in hypo‐γ‐globulinaemia with severe lymphocytopenia | |
| Rümke et al. | Immunoglobulin production in human mixed lymphocyte cultures: implications for co-cultures of cells from patients and healthy donors. | |
| Nishimaki et al. | Studies on immune complexes in rheumatoid arthritis | |
| Van Leeuwen et al. | Studies on quinine‐and quinidine‐dependent antibodies against platelets and their reaction with platelets in the Bernard‐Soulier syndrome | |
| Penner et al. | Immune complexes in primary biliary cirrhosis contain mitochondrial antigens | |
| US7989596B2 (en) | Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions | |
| MXPA05013402A (en) | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions | |
| Cantrell et al. | Prothrombin prevents fatal T cell–dependent anemia during chronic virus infection of mice | |
| JP6043807B2 (ja) | ヒト血液および血液製剤における非定型抗体の同定 | |
| McKerns | A study on the agglutination of erythrocytes | |
| Miescher | inhibiteur de la leucoagglutination 841 | |
| Minty | The interaction of phagocytic cells with immune complexes in rheumatoid arthritis | |
| CS231763B1 (cs) | Sposob přípravy prostriedku pre viazanie protilátek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: REDOX-REACTIVE REAGENTS L.L.C. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2623 DE 13-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |